Key Takeaways BSX is set to report Q4 results on Feb. 4, with revenues seen up 15.4% and earnings expected to rise 11.4%. BSX's MedSurg unit is expected to grow 11.4%, led by Endoscopy, Urology gains and Neuromodulation. BSX's Cardiovascular sales are seen up 17.5% on WATCHMAN uptake, FARAPULSE demand and strength. Boston Scientific (BSX) is slated to report fourth-quarter 2025 results on Feb. 4, before market open.The renowned medical device manufacturer posted earnings per share (EPS) of 75 cents in the l ...